In this article, we will take a look at some of the best US stocks under $10 to invest in.
Everyone seeks a stock that has good upside potential, but a stock that is cheap and has good prospects – that’s what a steal deal looks like. From leading investors to top analysts, the financial experts have stressed one thing: a cheap price doesn’t always imply the stock’s value.
In recent times, investors have shifted their focus from high-flying tech stocks to more valuable, mispriced companies, aiming to invest in genuine bargains. As Warren Buffett says,
“Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.”
For instance, a study by Josef Lakonishok, Andrei Shleifer, and Robert Vishny in 1994 highlights that value stocks tend to outperform glamour stocks by substantial margins. Thus, a smart investor is the one who acquires stocks when nobody wants them.
Our Methodology
In compiling a list of the 8 best US stocks under $10 to invest in, we have selected stocks that are favorites among investors. These stocks have positive upside potential and are recommended by research firms. The upside potential is calculated using the one-year price targets by Yahoo Finance and then ranked in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
8. Definitive Healthcare Corp. (NASDAQ:DH)
Upside potential as of August 16, 2025: 17.31%
BofA Securities has reaffirmed its Buy rating on Definitive Healthcare Corp. (NASDAQ:DH), while maintaining a price target of $4.50, implying a surge of 16.3%. This move comes as the company reports revenue and EBITDA above the research firm’s estimates and consensus forecasts.
In its latest earnings call, Definitive Healthcare Corp. (NASDAQ:DH) has raised full-year revenue guidance to $237-$240 million owing to better retention. This signals the company’s focus on streamlining its sales force. The management also announced the addition of 12 new enterprise clients within the quarter.
The company’s future looks promising, with analysts emphasizing retention rates, renewal trends, and the impact of operational changes. With strong initiatives in mind, Definitive Healthcare Corp. (NASDAQ:DH) is poised for growth.
Definitive Healthcare Corp. (NASDAQ:DH), headquartered in Massachusetts, is a provider of a SaaS healthcare commercial intelligence platform. Founded in 2011, the company has a well-diversified clientele in the biopharmaceutical, healthcare, and technology industries.
7. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV)
Upside potential as of August 16, 2025: 22.58%
Cantor Fitzgerald analysts have increased the price target on Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) to $9, up from $7, with an unchanged Overweight rating. This move follows the company’s strong quarterly performance, delivering a 29% year-over-year revenue growth.
Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) appears to be in a strong position under new management, outperforming its competitors and transitioning smoothly to a small-cap company with an equally promising future. Having said that, the stock has posted a return of 115% compared to the 16.35% one-year return of the S&P 500 (^GSPC).
The company’s commitment to building a durable and high-growth business with predictable results is what sets it apart from the others. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) also announced upward guidance during its latest earnings call. With such optimism surrounding the company, there’s no doubt that the investors are gravitating towards the stock.
Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), founded in 2013, is a Massachusetts-based provider of AI weapons detection that aids in artificial intelligence (AI)-based weapons detection. The core offerings of the company include Evolv Express, Evolv Insights Analytics Application, and Evolv eXpedite.
6. Shoals Technologies Group, Inc. (NASDAQ:SHLS)
Upside potential as of August 16, 2025: 38.34%
According to a research note, analysts at Wall Street Zen have upgraded Shoals Technologies Group, Inc. (NASDAQ:SHLS) to “Strong Buy” from “Hold.” This reflects increased investor confidence as the stock has been revised upwards by Roth Capital as well.
Many investors view Shoals Technologies Group, Inc. (NASDAQ:SHLS) as an interesting player in the market with a technology that is difficult to imitate and a backlog that is healthy. We can’t deny that clean and renewable energy is here to stay, and this paints the long-term picture quite optimistically.
What’s quite appealing is the company’s recent strategic initiatives that aim to enhance market share by attracting new customers and regaining old ones. The promotional strategies employed are considered the cause of the company’s declining gross margins, but as soon as the goal is achieved, Shoals Technologies Group, Inc. (NASDAQ:SHLS) will return to its long-term target.
Shoals Technologies Group, Inc. (NASDAQ:SHLS) is a Tennessee-based provider of electrical balance of system (EBOS) solutions and components. Incorporated in 1996, the company offers products utilized by the solar and battery storage industries.
5. National CineMedia, Inc. (NASDAQ:NCMI)
Upside potential as of August 16, 2025: 50.97%
Benchmark has reaffirmed its Buy rating on National CineMedia, Inc. (NASDAQ:NCMI), while maintaining a price target of $7.00, which reflects a potential surge of nearly 59.82% from current levels. This optimism is based on two points: advertising demand and theatrical attendance.
During the recent earnings call, the management highlighted strategic advancements, particularly scaling programmatic and self-serve offerings. The prospects from the upcoming releases are where things get interesting. Wicked for Good, Avatar: Fire & Ash, Zootopia, and Tron Ares are just a few movies that are anticipated to drive box office reacceleration.
With demand recovery across both national and local advertising channels, National CineMedia, Inc. (NASDAQ:NCMI) is forecasted to return approximately 50% in one year, according to estimates by Yahoo Finance analysts.
National CineMedia, Inc. (NASDAQ:NCMI), headquartered in Colorado, is a cinema advertising network in North America. Founded in 2006, the company, along with its subsidiaries, sells advertising to businesses and operates third-party theater circuits.
4. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
Upside potential as of August 16, 2025: 76.25%
Catherine Novack, an analyst at JonesTrading, has raised the price target on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to $9.00 from $6.00, while reaffirming a Buy rating on the stock. This potential upside of about 66.98% from the current price reflects the company’s strong position following FDA approval of its NDA resubmission.
Earlier on July 17, 2025, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s resubmitted New Drug Application (NDA) for its lead product, Reproxalap, aimed at the ophthalmic disorder dry eye disease. The regulatory authority has set December 16, 2025, as the target action date under the Prescription Drug User Fee Act (PDUFA) for completing its review.
This is when things get interesting. AbbVie is anticipated to pay $100 million upfront and share US profits if the approval is granted, which many believe will mitigate the risks associated with commercialization. The platform offered by Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) also includes follow-on assets like ADX-629 and ADX-2191.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a Massachusetts-based biotechnology company that engages in solutions aimed at immune-mediated and metabolic diseases. Incorporated in 2004, the company is committed to enhancing the patient’s well-being.
3. Arvinas, Inc. (NASDAQ:ARVN)
Upside potential as of August 16, 2025: 160.10%
XTX Topco Ltd has increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 194.2% during the first quarter, as disclosed in the company’s recent disclosure with the Securities & Exchange Commission. With the purchase of 51,658 shares, the firm now holds 78,257 shares of the company’s stock, valued at $549,000.
Arvinas, Inc. (NASDAQ:ARVN) recently achieved a milestone in its partnership with Pfizer to co-develop Vepdegestrant. The U.S. FDA is set to review the marketing application for the drug that is targeted at people with advanced or metastatic breast cancer who have previously received endocrine-based therapy. With a target action date of June 5, 2026, the solution is to address the unmet medical needs.
Considering the company’s robust balance sheet, management is confident in its resources to advance its exciting programs. Arvinas, Inc. (NASDAQ:ARVN) has prominent clinical and regulatory programs across its pipeline of PROTAC degraders, and that’s what makes it so compelling.
Arvinas, Inc. (NASDAQ:ARVN) is a Connecticut-based clinical-stage biotechnology company that engages in solutions to degrade disease-causing proteins. Founded in 2013, the company focuses on PROTAC (PROteolysis TArgeting Chimera) technology to power the body’s natural systems.
2. Savara Inc. (NASDAQ:SVRA)
Upside potential as of August 16, 2025: 174.34%
H.C. Wainwright has raised the price target on Savara Inc. (NASDAQ:SVRA) to $5.00 from $2.00, while upgrading the stock from Neutral to Buy. Much of this optimism is driven by the company’s agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) data requirements.
During a Type A meeting, Savara Inc. (NASDAQ:SVRA) resubmitted a Biologics License Application (BLA) for Molbreevi, after being refused a File letter from the agency. Andrew Fein, an analyst at H.C. Wainwright, sees improved results for the company’s BLA, which is set to be resubmitted in December.
Replacing the previous drug substance manufacturer, GEMA Biotech, the filing now includes Fujifilm Diosynth Biotechnologies. Many believe it to be a “make it or break it” event, and certainly, the company now appears poised to make it.
Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharmaceutical company based in Pennsylvania that provides solutions for rare respiratory diseases. Founded in 2007, the company is committed to developing innovative therapies to improve the lives of many.
1. Ovid Therapeutics Inc. (NASDAQ:OVID)
Upside potential as of August 16, 2025: 250.52%
Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a price target of $5.50, reflecting a potential surge of nearly 467% from the current price.
Much of this optimism surrounds the company’s OV329, which is anticipated to achieve $1 billion in sales in the U.S. alone, five years after its launch. With a focus on treating epilepsy and seizure-related neurological disorders, Ovid Therapeutics Inc. (NASDAQ:OVID) establishes a strong foundation in the market that is expected to continue growing.
Additionally, Ovid Therapeutics Inc. (NASDAQ:OVID) is developing KCC2 activators that are critical chloride pumps enabling neurons to control excessive electrical activity. This means that through these activators, the company can target multiple diseases in an attempt to open the door to transformative therapies that have both clinical and market prospects.
Ovid Therapeutics Inc. (NASDAQ:OVID) is a New York-based biopharmaceutical company that provides solutions for people suffering from epilepsies and seizure-associated neurological disorders. Incorporated in 2014, the company is committed to improving each day for its patients.
While we acknowledge the potential of OVID to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OVID and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
